Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Longevity & Anti-Ageing•Updated 2026-02-03•7 min read

    What Is Leuphasyl? Benefits, Research & Safety

    A 5-amino acid neuromuscular peptide that reduces expression lines through the enkephalin pathway, enhancing the effects of Argireline and SNAP-8.

    Share:X PostLinkedIn
    Also known as:
    Pentapeptide-18
    INCI: Pentapeptide-18
    DAnimal/cell evidence onlyUK: Licensed medicine (UK)WADA: Low sport risk

    UK summary: Cosmetic peptide regulated under UK cosmetics legislation. Enkephalin-pathway peptide marketed as an Argireline enhancer for expression lines. Effect size on its own is small.

    Quick Facts

    Category
    Longevity & Anti-Ageing
    Half-Life
    Effects persist while product remains on skin; must be applied consistently for maintained benefits; effects are cumulative with regular use
    UK Status
    Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.
    EU Status
    Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.

    Overview

    Leuphasyl (pentapeptide-18) is a neuromuscular peptide developed by Lipotec as a complementary ingredient to their Argireline family. Unlike Argireline and SNAP-8 which target the SNARE complex, Leuphasyl works through the enkephalin pathway—modulating neurotransmitter release via opioid-like receptor activation. This distinct mechanism makes Leuphasyl particularly valuable as an enhancer for other neuromuscular peptides. When combined with Argireline or SNAP-8, Leuphasyl creates a dual-pathway approach to reducing expression lines, with studies suggesting the combination may be more effective than either peptide alone. Leuphasyl's sequence (Tyr-D-Ala-Gly-Phe-Leu) is modelled on the natural enkephalin peptides that regulate neurotransmission. By mimicking these endogenous signalling molecules, Leuphasyl reduces the intensity of nerve signals that trigger facial muscle contractions—the root cause of expression lines like crow's feet, forehead wrinkles, and frown lines. Developed in the mid-2000s, Leuphasyl is now featured in advanced multi-peptide anti-ageing formulations, often alongside Argireline and SNAP-8 for comprehensive neuromuscular wrinkle reduction. **Important Note:** Leuphasyl is a cosmetic ingredient for topical use. It is not a pharmaceutical and effects are subtle compared to injectable neurotoxins. This information is for educational purposes.
    Evidence standards summary

    Leuphasyl — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

    Cosmetic peptide regulated under UK cosmetics legislation. Enkephalin-pathway peptide marketed as an Argireline enhancer for expression lines. Effect size on its own is small.

    02Human evidence grade

    DAnimal/cell evidence onlyStrength of evidence from published human trials.

    03Preclinical evidence grade

    CLimited human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.
    • EU: Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.
    • Notes: Leuphasyl (pentapeptide-18) is a fully approved cosmetic ingredient with established safety data. Despite working through enkephalin receptors, it has no opioid drug classification—effects are localised and cosmetic. Manufactured by Lubrizol (formerly Lipotec) and available globally in cosmetic formulations.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Equivalent to Botox.
    • Reverses ageing topically.

    07Common internet claims

    • Marketed as enkephalin-pathway cosmetic peptide.
    • Combined with Argireline / SNAP-8 in finished serums.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Synergistic with Argireline for wrinkles”DLimitedModerateSynergy claim is based on manufacturer studies; independent confirmation is limited.

    09Safety uncertainty score

    Low — well characterised

    Safety profile is well-characterised in published human data.

    10Known adverse signals

    • Generally well-tolerated topically.
    • Rare skin sensitivity.

    11Drug-interaction uncertainty

    Low

    Drug-interaction picture documented in the prescribing information.

    12Anti-doping status

    WADA: Low sport riskWADA strict-liability framing applies.

    13UK legal position

    UK: Licensed medicine (UK)

    Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.

    14EU legal position

    Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.

    15What this page cannot tell you

    • Whether independent finished-product trials demonstrate the manufacturer-claimed synergy.
    • Effect magnitude vs retinoids in comparative trials.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Independent RCT data are limited; most positive findings are manufacturer-funded.

    19Safer alternatives / established care pathways

    • Daily sunscreen + topical retinoid.
    • In-clinic botulinum toxin for genuine expression-line reduction.

    Related Safety Centre page → Clinic claim red flags

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is this an appropriate cosmetic addition to my routine?
    • Are there more evidence-backed actives to combine?

    Discovery & History

    Leuphasyl was developed by Lipotec Laboratories (Barcelona, Spain) as part of their expanding neuromuscular peptide portfolio following the commercial success of Argireline. The development strategy was to create a peptide that would work through a complementary mechanism, allowing enhanced results when combined with existing SNARE-targeting peptides. The design of Leuphasyl drew inspiration from the endogenous enkephalin peptides—naturally occurring opioid peptides that modulate neurotransmission throughout the nervous system. Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) are the primary enkephalins involved in pain modulation and neuromuscular regulation. Lipotec's researchers modified the enkephalin structure to create a cosmetically suitable peptide: - **Tyrosine (Tyr)** at position 1 for receptor binding - **D-Alanine** at position 2 for stability (the D-form resists enzymatic degradation) - **Glycine (Gly)** at position 3 for flexibility - **Phenylalanine (Phe)** at position 4 for receptor interaction - **Leucine (Leu)** at position 5 for signalling specificity This pentapeptide sequence activates enkephalin receptors on nerve terminals, reducing neurotransmitter release through a mechanism distinct from SNARE complex inhibition. The result is a complementary approach to reducing facial muscle contractions. Leuphasyl was positioned as an "enhancer" for Argireline rather than a replacement, with marketing focusing on the synergistic benefits of combining both peptides. This strategy proved successful, with many premium anti-ageing products now featuring the Argireline + Leuphasyl combination. Lipotec was acquired by Lubrizol in 2012, which continues to manufacture and market Leuphasyl as part of their neuromuscular peptide range alongside Argireline and SNAP-8.

    Mechanism of Action

    Leuphasyl exerts its wrinkle-reducing effects through the enkephalin pathway—a mechanism distinct from the SNARE complex inhibition of Argireline and SNAP-8: **Enkephalin Receptor Activation** Leuphasyl's sequence (Tyr-D-Ala-Gly-Phe-Leu) mimics natural enkephalin peptides, allowing it to bind to enkephalin receptors on peripheral nerve terminals in the skin. **Mechanism of Action:** 1. **Receptor Binding:** Leuphasyl binds to δ-opioid receptors (and possibly μ-opioid receptors) on nerve terminals 2. **Calcium Channel Modulation:** Receptor activation reduces calcium influx into nerve terminals 3. **Reduced Neurotransmitter Release:** Lower intracellular calcium decreases acetylcholine vesicle fusion and release 4. **Attenuated Muscle Contraction:** Less acetylcholine means weaker signals to facial muscles 5. **Expression Line Reduction:** Reduced muscle contraction intensity allows expression lines to soften **Comparison to SNARE-Targeting Peptides:** While Argireline and SNAP-8 interfere with the SNARE complex (the fusion machinery), Leuphasyl works upstream by reducing the calcium signal that triggers vesicle fusion. This creates two independent pathways to the same outcome: - **Argireline/SNAP-8:** Block the fusion mechanism → fewer vesicles release contents - **Leuphasyl:** Reduce the release signal → fewer vesicles attempt to fuse **Synergy with Argireline/SNAP-8:** When combined, these peptides create multiplicative rather than additive effects: - Two independent mechanisms targeting neurotransmitter release - Leuphasyl reduces the "trigger signal" while Argireline/SNAP-8 block the "release mechanism" - Studies suggest 25% enhanced efficacy when combined versus Argireline alone **No Systemic Opioid Effects:** Despite working through opioid receptors, Leuphasyl: - Acts locally on peripheral nerve terminals only - Does not cross the blood-brain barrier - Does not produce systemic opioid effects (no pain relief, sedation, or dependence) - Works at concentrations far below those needed for central effects **Reversible and Subtle:** Like other cosmetic peptides, Leuphasyl's effects are: - Fully reversible upon discontinuation - Subtle compared to injectable neurotoxins - Cumulative with consistent use - Safe for ongoing cosmetic application

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Reduces expression lines through enkephalin pathway (distinct from Argireline)
    • 2
      Enhances efficacy of Argireline/SNAP-8 when combined (synergistic effect)
    • 3
      Up to 25% improved wrinkle reduction versus Argireline alone in studies
    • 4
      Softens crow's feet, forehead lines, and frown lines
    • 5
      Dual-pathway approach provides comprehensive neuromuscular modulation
    • 6
      Excellent tolerability with rare side effects
    • 7
      Compatible with all skin types including sensitive skin
    • 8
      Suitable for use morning and evening
    • 9
      Works independently if used alone
    • 10
      No systemic opioid effects despite enkephalin receptor mechanism

    Claim vs Evidence

    How popular claims about Leuphasyl stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Synergistic with Argireline for wrinkles”DLimitedModerateSynergy claim is based on manufacturer studies; independent confirmation is limited.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageTypically used at 3-8% concentration in topical formulations; often combined with Argireline or SNAP-8 at similar concentrations
    FrequencyApplied twice daily to expression-prone areas (forehead, crow's feet, frown lines)
    DurationVisible improvements typically begin within 2-4 weeks; optimal results at 8+ weeks of consistent use
    NotesLeuphasyl is most effective when combined with Argireline or SNAP-8 for dual-pathway neuromuscular modulation. Apply to clean, dry skin on areas with expression lines before heavier products. Can be used morning and evening. For comprehensive anti-ageing, add collagen-stimulating peptides like Matrixyl to address structural ageing alongside expression line reduction.

    Administration Routes

    Routes studied in research settings (educational only):

    • Topical application in serums (most common)
    • Topical application in multi-peptide anti-ageing formulations
    • Topical application in eye contour treatments
    • Topical application in targeted wrinkle treatments
    Half-LifeStability
    Effects persist while product remains on skin; must be applied consistently for maintained benefits; effects are cumulative with regular useStable in properly formulated cosmetic products; the D-Alanine in position 2 provides enzymatic stability; should be stored in cool, dark conditions; typically 12-24 month shelf life

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Very well tolerated—side effects are rare
    • Mild skin irritation possible in sensitive individuals (uncommon)
    • Temporary redness at application site (rare)
    • Slight tingling sensation on initial application (occasional)

    Rare Risks & Concerns

    • Allergic reactions (very rare with peptides)
    • Eye irritation if product enters eyes
    • No systemic opioid effects at cosmetic concentrations

    Contraindications

    • Known allergy to peptides or specific formulation components
    • Active skin infections at application site
    • Open wounds (use only on intact skin)

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Approved cosmetic ingredient. Listed in the INCI dictionary as Pentapeptide-18. Available in over-the-counter skincare products without restrictions.

    🇪🇺 European Union

    Approved cosmetic ingredient under EU Cosmetics Regulation. Listed in CosIng database. No concentration restrictions for cosmetic use.

    Leuphasyl (pentapeptide-18) is a fully approved cosmetic ingredient with established safety data. Despite working through enkephalin receptors, it has no opioid drug classification—effects are localised and cosmetic. Manufactured by Lubrizol (formerly Lipotec) and available globally in cosmetic formulations.

    Clinical Studies Summary

    Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.

    This is the first integrative study to evaluate both peptides using combined computational and experimental approaches. Overall, these findings provide mechanistic insight into the anti-aging activity of Vialox and Leuphasyl and support their promise as effective, noninvasive dermocosmetic agents-offering a new avenue for healthier, youthful skin.

    Chem Biodivers. 2026View on PubMed

    Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis.

    Pharmacokinetic and drug-likeness properties were further assessed through ADMET (absorption, distribution, metabolism, excretion, and toxicity). The collective findings provide mechanistic insight into the molecular interactions and stability of Pentapeptide-18, reinforcing its potential as a safe, effective, and non-invasive candidate for advanced anti-aging skin care applications.

    Comput Biol Chem. 2026View on PubMed

    Looking for Leuphasyl?

    Source research-grade Leuphasyl from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Leuphasyl

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is this an appropriate cosmetic addition to my routine?
    • Are there more evidence-backed actives to combine?

    UK regulatory & safety context

    Clinic claim red flags

    Safety Centre guide

    Related Research Guides

    Peptides for Skin Health

    Read guide

    Peptides for Anti-Ageing

    Read guide

    Peptides for Wrinkle Reduction

    Read guide

    Peptide Comparisons

    Leuphasyl vs Argireline

    Compare peptides

    Leuphasyl vs Syn-Ake

    Compare peptides

    Argireline vs Matrixyl

    Compare peptides

    SNAP-8 vs Argireline

    Compare peptides

    Leuphasyl vs SNAP-8

    Compare peptides

    Combination Protocols

    GHK-Cu + Matrixyl + Argireline Anti-Ageing Stack

    View protocol

    Argireline + Leuphasyl + SNAP-8 Neuromuscular Stack

    View protocol

    Syn-Ake + Argireline + Leuphasyl Triple Neuromuscular Stack

    View protocol

    Quad-Pathway Neuromuscular Stack

    View protocol

    Related Peptides

    GHK-Cu

    A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.

    Learn more

    Matrixyl

    A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.

    Learn more

    Argireline

    A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.

    Learn more

    SNAP-8

    An enhanced 8-amino acid version of Argireline with improved penetration and efficacy for reducing expression lines through SNARE complex modulation.

    Learn more

    Syn-Ake

    A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.